Overview
Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Status:
Completed
Completed
Trial end date:
2007-12-01
2007-12-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known if stronger doses of chemotherapy given over a longer period of time are as well tolerated or as effective as less intensive chemotherapy. PURPOSE: This randomized phase III trial is studying intensive regimens of chemotherapy to see how well they work compared to nonintensive regimens of chemotherapy in treating older patients with acute myeloid leukemia or myelodysplastic syndrome.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Leukemia Research FundTreatments:
Cytarabine
Daunorubicin
Etoposide
Hydroxyurea
Idarubicin
Mitoxantrone
Thioguanine
Tretinoin
Criteria
DISEASE CHARACTERISTICS:- Acute myeloid leukemia (de novo or secondary) OR
- Myelodysplastic syndrome
- More than 10% myeloblasts in the bone marrow
- Refractory anemia with excess blasts
- Refractory anemia with excess blasts in transformation
- Chronic myelomonocytic leukemia
- No acute promyelocytic leukemia (FAB type M3)
- No blastic phase chronic myeloid leukemia
PATIENT CHARACTERISTICS:
Age:
- 60 and over (younger patients allowed if intensive chemotherapy not indicated)
Performance status:
- Not specified
Life expectancy:
- Not specified
Hematopoietic:
- Not specified
Hepatic:
- No liver function test ≥ 2 times normal (for non-intensive therapy arm)
Renal:
- Not specified
Cardiovascular:
- No myocardial infarction within past 6 months in patients receiving daunorubicin or
PSC 833
Other:
- No other concurrent active malignancy
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Not specified
Chemotherapy:
- No prior cytotoxic chemotherapy for leukemia
Endocrine therapy:
- Not specified
Radiotherapy:
- Not specified
Surgery:
- Not specified